105 studies found for:    "PCI-32765"
Show Display Options
Rank Status Study
1 Active, not recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
2 Completed A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
Condition: Healthy Volunteer
Interventions: Drug: PCI-32765 (Treatment A);   Drug: PCI-32765 (Treatment B);   Drug: PCI-32765 (Treatment C);   Drug: 13C6 PCI-32765 (reference)
3 Active, not recruiting A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
4 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
5 Completed A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Condition: Healthy Volunteers
Interventions: Drug: Sequence 1: PCI-32765;   Drug: Sequence 2: PCI-32765;   Drug: Sequence 3: PCI-32765;   Drug: Sequence 4: PCI-32765;   Drug: Sequence 5: PCI-32765
6 Active, not recruiting A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
7 Completed Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Conditions: B-Cell Lymphoma;   B-Cell Leukemia
Intervention: Drug: PCI-32765
8 Enrolling by invitation A Long-term Extension Study of PCI-32765 (Ibrutinib)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
9 Completed A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
Condition: Healthy Volunteer
Interventions: Drug: Treatment A: PCI-32765;   Drug: Treatment B: PCI-32765
10 Active, not recruiting Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: PCI-32765
11 Active, not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: BTK inhibitor PCI-32765;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: pharmacogenomic studies;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Active, not recruiting A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765;   Drug: Chlorambucil
13 Completed A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
14 Enrolling by invitation An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
15 Active, not recruiting A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765
16 Not yet recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
17 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
18 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
19 Completed
Has Results
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
20 Recruiting A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Ibrutinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years